Erasca
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3115 Merryfield Row Ste 300, San Diego, ...Phone Number
(858) 465-6511Website
www.erasca.comRevenue
$26.6 MillionStock Symbol
ERASIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Erasca
We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for RAS- and MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for approximately 5.5 million new patients diagnosed globally per year. We believe that to effectively shut down a pathway that signals as promiscuously as RAS/MAPK, a holistic approach must be taken to target not just individual nodes, but multiple nodes and cooperative mechanisms in parallel. Consequently, we are pursuing three therapeutic strategies that may be used in combination to comprehensively, and perhaps synergistically, shut down the RAS/MAPK pathway.Explore more
Erasca Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Erasca your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Erasca had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Erasca, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Erasca is spiking on competitors!
Earning: See what the market has to say on Erasca recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Erasca has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Erasca has new funding data
Congratulate Masked Content for being promoted to Masked Content at Erasca
Product Launch: Get notified when Erasca launches new products
Recommended Actions
Find VP level buyers at Erasca
Find 2 more new buyers
Compare Similar Companies to Erasca
Compare insights from companies similar to Erasca, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$97.4M
201-500
Public
$237.2M
1997
John DesjarlaisExecutive Vice President & Research & Scientific Chief & Officer
Company Profile Activity
Activity Insights
Erasca is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Erasca is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Erasca.
Erasca financials insights
Gather financial insights about Erasca, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$64M
2020
Series B
$200M
2021
Share Placement
$300M
Erasca Tech Stack
A closer look at the technologies used by Erasca
Most Recent Scoops
Open Position
Person-Based
Medical Research
Person-Based
Contracts
Person-Based
Lawsuits, Legal Affairs, Pharmaceuticals
Person-Based
Medical Research
Erasca News & Media
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combinationGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Erasca, Inc. (ERAS)
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”).Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Charles S. Fuchs, M.D., M.P.H., as president of research and development (R&D), effective immediately. Dr. Fuchs brings more than three decades of leadership in oncology, with deep expertise across drug development, sciErasca, Inc. Investor Alert: Contact SBS by August 10, 2026 for Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, Aug. 10, 2026 /PRNewswire/ -- Schall Brown & Schwartz LLP, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Erasca, Inc. ("Erasca" or "the Company") (NASDAQ: ERAS) for violations of §§10(b) and 20(a) of the Securities Exchange...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Erasca
Sign Up For FreeTo access detailed company insights
We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for RAS- and MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for approximately... Read More
